Induction Therapy with S-1 for Spindle Cell Carcinoma of the External Auditory Canal
- Corresponding Author:
- Toshiaki Yamanaka
Department of Otolaryngology-Head and Neck Surgery
Nara Medical University School of Medicine
Kashihara, Nara, 634-8522, Japan
E-mail: [email protected]
Received date: October 04, 2013; Accepted date: October 30, 2013; Published date: November 27, 2013
Citation: Yamanaka T, Shimizu N, Enomoto Y, Hosoi H (2013) Induction Therapy with S-1 for Spindle Cell Carcinoma of the External Auditory Canal. Otolaryngology 3:149. doi:10.4172/2161-119X.1000149
Copyright: © 2013 Yamanaka T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
We report an unusual case of spindle cell carcinoma of the external auditory canal, which responded well to two weeks’ treatment with the oral fluoropyrimidine anticancer drug S-1 (80 mg/body/day) followed by surgical resection. After the S-1 treatment, the tumor was significantly reduced in size, and a pathological examination only detected small lesions composed of malignant cells. We then conducted a lateral temporal bone resection combined with left modified neck dissection. The patient did not demonstrate any evidence of local recurrence or distant metastasis during the 5-year follow-up period. It is suggested that S-1 played an important role in reducing the size of the tumor to allow radical resection of the tumor with a sufficient surgical margin in the present case and that induction chemotherapy with S-1 prior to surgery might be an effective treatment strategy for controlling spindle cell carcinoma of the ear.